Tranexamic Acid Dosing for Total Joint Arthroplasty

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of increasing doses of tranexamic acid (TXA) on limiting blood loss during total knee and total hip arthroplasty as defined by a change in hemoglobin from pre-operative baseline to the first post-operative day.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Patients undergoing primary unilateral total knee arthroplasty or primary unilateral total hip arthroplasty under spinal anesthesia at Columbia University Medical Center/ New York Presbyterian Hospital.

Exclusion Criteria:

• Non-English speaking.

• Patient refusal to participate.

• Weight exceeding 100kg.

• Baseline hemoglobin of less than 10.

• Repeat, revision, or bilateral surgery.

• Known sensitivity or allergy to Tranexamic Acid.

• Active intra-vascular clotting.

• History of coagulopathy or congenital thrombophilia.

• Thromboembolic event in the 12 months prior to enrollment.

• Percutaneous coronary intervention requiring a drug eluting stent in the 12 months prior to enrollment.

• History of anticoagulant medication use unless stopped prior to surgery as recommended by and in accordance with the American Society of Regional Anesthesia Guidelines.

• Use of a general anesthetic in the current anesthetic.

• Blood transfusion for a hemoglobin value which deviates from the study's transfusion protocol.